Here is an analytical blog comparing the IQVIA MFR...

Guest Editorial by Sharadha Iyer on the urgent need to close the gender gap in the Indian Pharma Industry

Key Point from the Q &A with Dr. Mandar...

COVID-19 has accelerated the shift in how pharma was engaging with HCPs, professional organisations and even patients in India from a sales to more of a scientific, unbiased and balanced marketing communications. As one of the business leader from a prominent MNC said, “For the first time we are seeing a certain shift in HCP’s preference for scientific communication for innovators companies. MSLs and scientific operation teams will be playing a key role in the near future.”

More than digitalizing your product promotions, the case calls for building and engaging your brand community through digital solutions that create memorable customer experiences. With the new normal emerging, the traditional Pharma commercial model needs to be relooked by exploring alternative channels of engagement, which offer opportunities to create value for customers. Company-specific digital adoption workshops to experience how a brand can be promoted using the omnichannel approach with field force involvement.

India’s caesarean section debate is drifting toward polarisation. On one...

In big pharma, leadership changes are rarely impulsive. They...

How a niche Indian topicals manufacturer outgrew its CDMO...

Transparency, Trust, and the Problem of “Invisible Evidence” in...

India’s pharmaceutical industry occupies a unique and powerful position...

India’s caesarean section debate is drifting toward polarisation. On one...

In big pharma, leadership changes are rarely impulsive. They...

How a niche Indian topicals manufacturer outgrew its CDMO...

Transparency, Trust, and the Problem of “Invisible Evidence” in...

India’s pharmaceutical industry occupies a unique and powerful position...

India’s caesarean section debate is drifting toward polarisation. On one...

In big pharma, leadership changes are rarely impulsive. They...

How a niche Indian topicals manufacturer outgrew its CDMO...

Transparency, Trust, and the Problem of “Invisible Evidence” in...

India’s pharmaceutical industry occupies a unique and powerful position...

India’s caesarean section debate is drifting toward polarisation. On one...

In big pharma, leadership changes are rarely impulsive. They...

How a niche Indian topicals manufacturer outgrew its CDMO...

Transparency, Trust, and the Problem of “Invisible Evidence” in...

India’s pharmaceutical industry occupies a unique and powerful position...